Pancreatic Cancer Research

ResearcherMemorial Sloan Kettering Cancer CenterNo recent work listed

Georgios Antonios Margonis

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-4894-5743; OpenAlex author ID A5027737835. Sources: OpenAlex.

Their work

Papers
9 (first author 2, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
83
Papers, trials and grants by year

2015: 1 paper · 2016: 1 paper · 2017: none · 2018: none · 2019: 1 paper · 2020: 1 paper · 2021: 3 papers · 2022: none · 2023: 2 papers

Papers 9

  1. Gp130 is expressed in pancreatic cancer and can be targeted by the small inhibitor molecule SC144. Co-author DOI 10.1007/s00432-022-04518-9↗
  2. Performance of the 7 th and 8 th Editions of the American Joint Committee on Cancer Staging System in Patients with Intraductal Papillary Mucinous Neoplasm-Ass… Co-author DOI 10.1097/sla.0000000000005313↗
  3. Toward an Optimized Staging System for Pancreatic Ductal Adenocarcinoma: A Clinically Interpretable, Artificial Intelligence-Based Model. First author DOI 10.1200/cci.21.00001↗
  4. Peptide Signatures for Prognostic Markers of Pancreatic Cancer by MALDI Mass Spectrometry Imaging. Co-author DOI 10.3390/biology10101033↗
  5. Rethinking the TNM Classification Regarding Direct Lymph Node Invasion in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/cancers14010201↗
  6. Novel methods for in vitro modeling of pancreatic cancer reveal important aspects for successful primary cell culture. Co-author DOI 10.1186/s12885-020-06929-8↗
  7. Neoadjuvant FOLFIRINOX in Patients With Borderline Resectable Pancreatic Cancer: A Systematic Review and Patient-Level Meta-Analysis. Co-author DOI 10.1093/jnci/djz073↗
  8. Is resection of pancreatic adenocarcinoma with synchronous hepatic metastasis justified? A review of current literature. First author DOI 10.1111/ans.13738↗
  9. Impact Total Psoas Volume on Short- and Long-Term Outcomes in Patients Undergoing Curative Resection for Pancreatic Adenocarcinoma: a New Tool to Assess Sarcop… Co-author DOI 10.1007/s11605-015-2835-y↗

Closest collaborators

The 25 strongest of 83 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Katharina Beyer · 6 shared papers, 2020–2023 · strength 0.77
  2. Carsten Kamphues · 5 shared papers, 2020–2023 · strength 0.59
  3. Matthew John Weiss · 4 shared papers, 2015–2023 · strength 0.35
  4. Florian Nino Loch · 3 shared papers, 2020–2021 · strength 0.35
  5. Ioannis Pozios · 2 shared papers, 2021–2023 · strength 0.29
  6. Christopher Lee Wolfgang · 3 shared papers, 2015–2023 · strength 0.29
  7. Hendrik Seeliger · 2 shared papers, 2021–2023 · strength 0.27
  8. Alessandra Pulvirenti · 2 shared papers, 2021–2023 · strength 0.24
  9. Frederick Klauschen · 2 shared papers, 2020–2021 · strength 0.23
  10. Nina A. Hering · 1 shared paper, 2023 · strength 0.18
  11. Thomas Knösel · 1 shared paper, 2023 · strength 0.18
  12. Christiane J. Bruns · 1 shared paper, 2023 · strength 0.18
  13. Carlos F. Fernandez-del Castillo · 1 shared paper, 2023 · strength 0.15
  14. Peter J. Allen · 1 shared paper, 2023 · strength 0.15
  15. Kevin C. Soares · 1 shared paper, 2023 · strength 0.15
  16. Vicente Morales‐Oyarvide · 1 shared paper, 2023 · strength 0.15
  17. Bas Groot Koerkamp · 2 shared papers, 2019–2021 · strength 0.15
  18. Oliver Klein · 1 shared paper, 2021 · strength 0.13
  19. Fiona Speichinger · 1 shared paper, 2021 · strength 0.12
  20. Mihnea Paul Dragomir · 1 shared paper, 2021 · strength 0.12
  21. Simon Schallenberg · 1 shared paper, 2021 · strength 0.12
  22. Timothy Michael Pawlik · 2 shared papers, 2015–2016 · strength 0.11
  23. Lukas Ehlen · 1 shared paper, 2020 · strength 0.10
  24. Jin Peng He · 1 shared paper, 2021 · strength 0.09
  25. Dimitris Bertsimas Ioannis · 1 shared paper, 2021 · strength 0.09

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.